A review on the effectivity of chemotherapies with gemcitabine in ovarian cancers;A petefészekrákokban alkalmazott gemcitabinkezelés eredményessége az irodalmi adatok tükrében

Orvosi Hetilap

Volumn 146, Issue 46, 2005, Pages 2351-2357

  Lehoczky, Ottó ^a  

^a Nogyógyászati Osztály ^*  (Hungary)

Author keywords

Chemotherapy; Gemcitabine; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; MORTALITY; NEUTROPENIA; OVARY CANCER; PUBLICATION; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; FEMALE; OVARY TUMOR; REVIEW; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; NEUTROPENIA; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33644838805     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Barlow, C., Nystrom, M., Oesterling, C. és mtsai: Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br. J. Cancer, 2004, 90, 1318-1322.
2. Belpomme, D., Krakowski, I., Beauduin, M. és mtsai: Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study. Gynecol. Oncol., 2003, 91, 32-8.
3. Bilgin, T., Özalp, S., Yalcin, Ö. T. és mtsai: Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur. J. Gynaec. Oncol., 2003, 24, 169-170.
4. Bruzzone, M., Mencoboni, M., Mammoliti, S. és mtsai: Second line chemotherapy (CT) with gemcitabine (G) and vepesid (VP16) in platinum resistant (DDP-R) advanced ovarian cancer (AOC) patients. Amerikai Klinikai Onkológiai Társaság 2004. évi gyulése. Absztrakt No. 5082 (www:asco.org/publications).
5. Common Toxicty Criteria Manual, version 2,0. National Cancer Institute: Cancer therapy evaluation program, (http://www.rtog.org/members/toxicity/ ctcmanual6-1-99.pdf, lekérdezés ideje 2005. május 2.)
6. Copeland, L. J., Bookman, M., Trimble, E. és mtsai: Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol. Oncol., 2003, 90, S1-7.
7. D'Agostino, G., Amant, F., Berteloot, P. és mtsai: Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol. Oncol., 2003, 88, 266-269.
8. D'Agostino, G., Ferrandina, G., Ludovisi, M. és mtsai: Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br. J. Cancer, 2003, 89, 1180-1184.
9. du Bois, A., Luck, H. J., Pfisterer, J. és mtsai: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer. A dose finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol., 2001, 12, 1115-1120.
10. Friedlander, M., Millward, M. J., Bell, D. és mtsai: A phase II study of gemcitabine in platinum pretreated patients with advanced epithelial ovarian cancer. Ann. Oncol., 1998, 9, 1343-1345.
11. Garcia, A. A., O'Meara, A., Bahador, A. és mtsa: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol., 2004, 93, 493-498.
12. Geertsen, P., Hansen, M., Stroyer, I. és mtsai: Combination chemotherapy with platinum, paclitaxel and gemcitabine in patients with relapsed ovarian cancer. Amerikai Klinikai Onkológiai Társaság 1999. évi Gyulése. Absztrakt No. 1395 (www. asco.org/publications).
13. Germano, D., Bilancia, D., Di Nota, A. és mtsai: Bi-weekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatin pretreated patients with relapsed ovarian cancer (roc): Preliminary data of a phase II trial. Amerikai Klinikai Onkológiai Társaság 2004. évi gyulése. Absztrakt No. 5104 (www.asco.org/publications).
14. Goff, B. A., Thompson, T., Greer, B. E. és mtsai: Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602) Am. J. Obstet. Gynecol., 2003, 188, 1556-1562.
15. Hanjani, P., Shahin, M. S., Nolte, S. A.: Phase II evaluation of weekly docetaxel and gemcitabine combination chemotherapy in recurrent ovarian cancer. Amerikai Klinikai Onkológiai Társaság 2004. évi gyulése. Absztrakt No. 5115 (www.asco.org/publications).
16. Hansen, S. W., Anderson, H., Boman, K. és mtsai: Gemcitabine, Carboplatin, and Paclitaxel (GCP) as First-Line Treatment of Ovarian Cancer FIGO Stages IIB-IV. Amerikai Klinikai Onkológiai Társaság 1999. évi gyulése. Absztrakt No. 1379 (www.asco.org/publications).
17. Hansen, S. W.: Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol., 2002, 29 (Suppl. 1.), 17-19.
18. Heinemann, V., Hertel, L. W., Grindey, G. B. és mtsa: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res., 1988, 48, 4024-4031.
19. - Holloway, R. W., Finkler, N. J., Nye, L. P e′s mtsai: Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial. Amerikai Klinikai Onkolo′giai Társaság 2004. évi Gyulése. Absztrakt No. 5090 (www.asco.org/publications).
20. Kose, M. F., Sufliarsky, J., Beslija, S. és mtsai: A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol. Oncol., 2005, 96, 374-380.
21. Krakowski, I., Petit, T., Kayitalire, L. és mtsai: Gemcitabine (GEMZAR [trade]) in combination with cisplatin (cp) in advanced ovarian cancers (aoc): a phase II) study. Amerikai Klinikai Onkológiai Társaság 1998. évi gyulése. Absztrakt No. 1373 (www.asco.org/publications).
22. Lehoczky O., Bagaméri A., Udvary J. és mtsa: Kiújult petefészekrákok második vonalú paclitaxel kezelése. Orv. Hetil., 2001, 142, 2299-2301.
23. Lehoczky O., Bagaméri A., Lehoczky Gy. és mtsa: Kiújult petefészekrákos betegek topotecan kezelésével szerzett korai tapasztalatok. Orv. Hetil., 2002, 143, 15-18.
24. Lin, F. S., Ho, E. E. S., Hung, M. J. és mtsai: Triplet combination of gemcitabinc, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. Gynecol. Oncol., 2004, 94, 393-397.
25. Look, K. Y., Bookman, M. A., Schol, J. és mtsai: Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol., 2004, 92, 93-100.
26. Lund, B., Hansen, O. P., Theilade, K. és mtsai: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst., 1994, 86, 1530-1533.
27. Markman, M., Webster, K., Zanotti, K. e′s mtsai: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxcl refractory ovarian cancer. Gynecol. Oncol., 2003, 90, 593-596.
28. McGuire, W. P., Hoskins, W. J., Brady, M. F. e′s mtsai: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
29. Micha, J. P., Goldstein, B. H., Rettenmaier, M. A. és mtsai: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol. Oncol., 2004, 94, 719-724.
30. Mutch, D. G.: Gemcitabine combination chemotherapy of ovarian cancer. Gynecol. Oncol., 2003, 90, S16-20.
31. Nagourney, R. A., Brewer, C. A., Radecki, S. és mtsai: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol., 2003, 88, 35-39.
32. Nogue, M., Cirera, L., Arcusa, M. és mtsai: Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Amerikai Klinikai Onkológiai Társaság 1998. évi gyulése. Absztrakt No. 1377 (www.asco.org/publications).
33. Nogue, M., Cirera, L., Arcusa, A. és mtsai: Phase II study of gemcitabine and cisplatin in chemonaivc patients with advanced epithelial ovarian cancer. Anticancer Drugs, 2002, 13, 839-845.
34. Papadimitriou, C. A., Fountzilas, G., Aravantinos G. és mtsai: Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol. Oncol. 2004, 92, 152-159.
35. Pfisterer, J., Plante, M., Vergote, I. és mtsai: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Amerikai Klinikai Onkológiai Társaság 2004. évi gyulése. Absztrakt No. 5005 (www.asco.org/publications).
36. Piccart, M. J., Bertelsen, K., James, K. és mtsai: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst., 2000, 92, 699-708.
37. Pira, B., Rabinovich, A.: Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur. J. Gynaecol. Oncol., 2004, 25, 449-452.
38. Pulay T., Csömör S., Faluhelyi Zs. és mtsai: A Caelyx helye a petefészekrák másodvonalbeli kezelésében. Magyar Onkológia, 2004, 48, 97-99.
39. Raspagliesi, F., Zanaboni, F., Vecchione, F. és mtsai: Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology, 2004, 67, 376-381.
40. Rose, P. G., Mossbruger, K., Fusco, N. és mtsai: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol., 2003, 88, 17-21.
41. Roychowdhury, D. F., Cassidy, C. A., Peterson, P. és mtsa: A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest. New Drugs, 2002, 20, 311-315.
42. Salimichokami, M., Vahid, A. A., Mir, M. R.: Phase 2 study of weekly triplet regimen of docetaxel, carboplatin and gemcitabinc in recurrent platinum-sensitive epithelial ovarian cancer. Amerikai Klinikai Onkológiai Társaság 2004. évi gyulése. Absztrakt No. 5150 (www.asco.org/publications).
43. Sauer-Heilborn, A., Kath, R., Schneider, C. P. és mtsa: Severe non-haematological toxicity after treatment with gemcitabine. J. Cancer Res. Clin. Oncol., 1999, 125, 637-640.
44. Sehouli, J., Stengel, D., Oskay, G. és mtsai: A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann. Oncol., 2002, 13, 1749-1755.
45. Shapiro, J. D., Millward, M. J., Rischin, D. és mtsai: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol., 1996, 63, 89-93.
46. Silver, D. F., Piver, M. S.: Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube and peritoneum. Am. J. Clin. Oncol., 1999, 22, 450-452.
47. Tewari, D., Monk, B. J., Hunter, M. és mtsai: Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest. New Drugs, 2004, 22, 475-480.
48. Vasey, P., Atkinson, R., Osborne, R. és mtsai: Carboplatin (Cb) followed sequentially by docetaxel (D) ± gemcitabine (G) in ovarian, peritoneal and fallopian tube cancers; Results of SCOTROC 2A. Amerikai Klinikai Onkológiai Társaság 2003. évi gyulése. Absztrakt No. 1804 (www.asco.org/publications).
49. Villella, J., Marchetti, D., Odunsi, K. és mtsai: Response of combination platinum and gemcitabinc chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol. Oncol., 2004, 95, 539-545.
50. von Minckwitz, G., Bauknecht, T., Visseren-Grul, C. M. és mtsa: Phase II study of gemcitabine in ovarian cancer. Ann. Oncol., 1999, 10, 853-855.